13 Aug.

The future of health in China and the US: Embracing new disruption

China Issues

Thursday, 11:00 a.m.  ET | 1 hr
Credits offered: CPE Event language: English

Participants will review key industry trends and learn about new opportunities and challenges that are reshaping the US and China LSHC market.

View On-demand

Key takeaways

Host: Lili Zheng, partner, Deloitte Tax LLP

1 Overview CPE credit | Specialized Knowledge

How did the US and China life sciences and health care (LSHC) sector perform in the past 18 months with many companies facing headwinds such as lower GDP growth, US-China trade frictions, and the COVID-19 pandemic? These and other new dynamics could influence the future of health in the two countries.  We'll discuss:

  • Recent capital markets trends, including emerging market demand, policy changes, and exit channels.
  • Cross-border implications for LSHC businesses, including M&A.
  • How tech giants are reshaping the LSHC landscape.

Meet the speakers

Lili Zheng

Lili Zheng

Partner | Deloitte Tax LLP

Lili is a senior US International Tax partner with substantial experience in cross-border tax planning. Currently serving as the deputy managing partner of the US Chinese Services Group, she is responsible for Deloitte's overall cross-functional services to Chinese clients investing in the US. She also leads our services in advising multinational corporations (MNCs) on their cross-border investments between the US, China, and Asia Pacific. Lili has extensive knowledge in consulting with clients in various industries on their cross-border investment structure, M&A, entry and exit strategies.

Simon Gisby

Simon Gisby

Principal | Life Sciences & Health Care

Simon Gisby is a principal in the M&A and the Life Sciences & Health Care practices at Deloitte and is the Future of Health leader for Deloitte US Risk & Financial Advisory practice. He has experience in all aspects of life sciences and health care M&A strategy and execution, joint ventures, and partnerships. His clients include global pharmaceutical and medical device companies, health plans, health systems, and health care information technology companies. He has been awarded the M&A Advisor Healthcare Deal of the Year Award and Healthcare Restructuring Deal of the Year Award, is a frequent presenter on health care M&A and the future of health, and has contributed to numerous articles on M&A and health care. He is a Chartered Financial Analyst and a graduate of Oxford University.

Jens Ewert

Jens Ewert

China LSHC Industry Leader

Jens Ewert, is a Senior Partner with Deloitte based in Shanghai office and China Firm since 2002, and has over 30 years of working experience in the professional services. For many years already, he is a member of Deloitte China Eastern Region Management team. Jen's responsibilities include: Our services to Multinational Clients (MNC) in China. This covers our combined store front of Advisory services (Consulting, Financial Advisory, Tax and Risk Advisory) as well as our Audit & Assurance services.  He is also the lead partner for some selected Clients accounts beyond China across the Asia Pacific region through various industries. Leading the Deloitte China Life Sciences & Health Care Industry  – covering an dedicated industry team comprising over 600+ partners and professionals focused on working with Life Science & Pharma companies as well as Healthcare and related services groups. Jens is currently a Board member at the EUCCC Shanghai Chapter and the National Chair of the Investment Working group since 2016 at the EU Chamber in China. He started his career in 1988 in France, and other than China, he has been living and working Hungary (1990-94), the US, Vietnam (1995-98) and Indonesia (1998-99). Jens holds German and French nationalities, and calls France – beyond Shanghai - his home. He received his education in France (Paris), University Paris Dauphine and the Institut des Sciences Politiques de Paris, and holds a CPA Australia license. He is a passionate Tennis and Golf player in Shanghai, when time permits.

Bob Chen

Bob Chen

China LSHC Financial Advisory Leader

Bob Chen is a partner at Deloitte China, leading the Financial Advisory for China Life Sciences and Health Care Industry. Bob has 17 years of experience in auditing, due diligence and corporate value assessment, merger and acquisition negotiation support, and has advised over 300 domestic mergers and acquisitions and 60 cross-border mergers and acquisitions. Bob spent 2 years at Deloitte's New York mergers and acquisitions team, completing nearly 20 M&A deals in Deloitte USA. Bob focused on mergers and acquisitions in life sciences and health care industry, with in-depth professional experience and insights in the industry. He led the roadshow of Deloitte global life sciences and health care M&A activities in mainland China and Hong Kong, and organized and spoke at the  Deloitte event at JP Morgan Healthcare Conference in San Francisco. He is committed to building bridges for successful acquisition between Chinese companies and investors, as well as financial due diligence in China's domestic life sciences and health care industry. Bob is a frequent speaker at seminars and Dbrief lectures on mergers and acquisitions in the healthcare industry. As a specialist in Deloitte's healthcare industry, his industry insights are cited by Standard and Poor's S.P., China News Agency, National Business Daily, ICS, and so on. Bob graduated from Shanghai Jiaotong University with a bachelor's degree in economics & finance and computer science. He has AICPA, CMA, CIA Professional Qualification.

Dbriefs resources

Thursday, 13 Aug 2020 11:00 a.m. ET
Share Share event on social
View On-demand